Q3 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Zura Bio in a research report issued on Monday, November 4th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings of ($0.14) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.62) EPS.

A number of other research analysts have also recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a report on Monday, October 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Finally, Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday. They set an “outperform” rating and a $15.00 price objective for the company. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zura Bio has a consensus rating of “Buy” and an average price target of $16.75.

Zura Bio Stock Performance

Shares of ZURA stock opened at $4.30 on Wednesday. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35. The firm has a fifty day moving average of $4.17 and a 200-day moving average of $4.09.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZURA. Affinity Asset Advisors LLC acquired a new stake in shares of Zura Bio in the 1st quarter valued at approximately $1,157,000. Bank of New York Mellon Corp increased its stake in shares of Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after purchasing an additional 6,412 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares in the last quarter. Great Point Partners LLC raised its stake in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares during the period. 61.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.10% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.